Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, Open-Label, Single-Arm, Phase I Study with Dose Expansion Cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Next Previous
Trial Profile

A Single-Center, Open-Label, Single-Arm, Phase I Study with Dose Expansion Cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Sacituzumab govitecan (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

  • 02 Dec 2025 Planned End Date changed from 7 Sep 2026 to 1 Jul 2027.
  • 02 Dec 2025 Planned primary completion date changed from 7 Sep 2026 to 1 Jul 2026.
  • 31 Oct 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top